Ocular Therapeutix/$OCUL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Ocular Therapeutix

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Ticker

$OCUL
Sector
Primary listing

Employees

274

OCUL Metrics

BasicAdvanced
$2B
-
-$1.28
1.49
-

What the Analysts think about OCUL

Analyst ratings (Buy, Hold, Sell) for Ocular Therapeutix stock.

Bulls say / Bears say

As of June 30, 2025, Ocular Therapeutix held $391.1 million in cash and cash equivalents, providing substantial liquidity to fund its commercial operations and advance clinical programs. (SEC Filing)
The FDA granted Special Protocol Assessment for the registrational NPDR trial of AXPAXLI, aligning study design with regulatory expectations and reducing approval risk. (GlobeNewswire)
DEXTENZA end-user unit sales rose 5% year-over-year and net product revenue climbed 26% sequentially in Q2 2025, demonstrating resilient demand despite reimbursement pressures. (GlobeNewswire)
Total net product revenue in Q2 2025 fell 18.1% to $13.4 million year-over-year, as evolving reimbursement challenges weighed on DEXTENZA sales. (SEC Filing)
Research and development expenses rose to $51.1 million in Q2 2025 from $28.9 million in Q2 2024, reflecting intensifying spend on Phase 3 trials and adding near-term cash burn pressure. (GlobeNewswire)
Key Phase 3 trial readouts for SOL-1 and SOL-R are not expected until Q1 2026 and H1 2027, making valuation highly sensitive to binary clinical outcomes. (TipRanks)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

OCUL Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

OCUL Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $OCUL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs